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Prion diseases are caused by conversion of a normal cell-surface glycoprotein (PrPC) into a conformationally altered isoform (PrPSc) that is
infectious in the absence of nucleic acid. Although a great deal has been learned about PrPSc and its role in prion propagation, much less is known
about the physiological function of PrPC. In this review, we will summarize some of the major proposed functions for PrPC, including protection
against apoptotic and oxidative stress, cellular uptake or binding of copper ions, transmembrane signaling, formation and maintenance of
synapses, and adhesion to the extracellular matrix. We will also outline how loss or subversion of the cytoprotective or neuronal survival activities
of PrPC might contribute to the pathogenesis of prion diseases, and how similar mechanisms are probably operative in other neurodegenerative
disorders.
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Prion diseases result from conversion of a normal, cell-
surface glycoprotein (PrPC) into a conformationally altered
isoform (PrPSc) that is infectious in the absence of nucleic acids.
Although we know a great deal about the role of PrPSc in the
disease process, the normal, physiological function of PrPC has
remained enigmatic. Attempts to deduce the function of PrPC
from the phenotypes of PrP-null mice have been uninformative,
since lines of these mice in which the adjacent Doppel (Dpl)
gene is not artifactually up-regulated display no major
anatomical or developmental deficits [1,2]. Even mouse lines
in which the PrP gene is deleted postnatally using a conditional
Cre–Lox system are phenotypically relatively normal, arguing
against the existence of other proteins that compensate for
essential PrP functions during development [3]. Parts of the
PrPC sequence have been highly conserved in evolution [4],
suggesting important biological roles for the protein.⁎ Corresponding author. Tel.: +1 314 362 4690; fax: +1 314 747 0940.
E-mail address: dharris@wustl.edu (D.A. Harris).
1 These two authors contributed equally to this work.
0925-4439/$ - see front matter © 2007 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbadis.2007.02.011Investigating the biological activity of PrPC is likely to be
crucial for understanding the pathogenesis of prion diseases,
since alteration of this function could play a role in the disease
process. In this review, we will summarize some of the major
proposed functions for PrPC, with a particular emphasis on a
role for the protein in protection from cellular stress. We will
also outline how gain, loss, or subversion of PrPC function can
play a role in the pathogenesis of prion diseases, and how
similar mechanisms may be operative in other neurodegenera-
tive disorders.
2. Cellular biology of PrPC
PrPC is expressed beginning early in embryogenesis, and in
the adult it is present at highest levels in neurons of the brain and
spinal cord [5,6]. PrPC is also found at lower levels in glial cells
of the CNS as well as in a number of peripheral cell types [7,8].
Most PrPC molecules are normally localized on the cell surface,
where they are attached to the lipid bilayer via a C-terminal,
glycosyl-phosphatidylinositol (GPI) anchor [9]. The biosyn-
thetic pathway followed by PrPC is similar to that of other
membrane and secreted proteins, involving synthesis on ER-
attached ribosomes, transit to the Golgi, followed by delivery to
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two N-linked oligosaccharide chains of the complex type.
Although most cell-surface PrPC is found in lipid rafts, some of
the protein is transferred to clathrin-coated pits where it is
subjected to constitutive endocytosis and recycling [11–14].
3. Identification of proteins that interact with PrPC
A powerful strategy for elucidating the physiological
function of PrPC would be to identify other cellular proteins
with which PrPC interacts. At least some of these interactors are
likely to be components of the physiological pathways in which
PrP plays a role. Over the years, a number of candidates have
been identified as potential PrP-binding partners using conven-
tional yeast two-hybrid screens, co-immunoprecipitation, cross-
linking and other methods (Table 1) (reviewed in [15]). Several
of the candidates listed in Table 1 (STI-1, N-CAM, Bcl-2,
caveolin) will be discussed below, in conjunction with the
cellular function of PrP in which they are purported to play a
role. In almost every case, however, the physiological relevance
of the proposed interactions remains uncertain. Some of the
putative interactors are primarily or exclusively cytoplasmic
proteins, and so would be unlikely to associate directly with PrP,
which is localized to the outer face of the plasma membrane and
to the lumen of organelles in the secretory pathway. One
example of such a candidate is the laminin receptor precursor
(LRP), which was originally identified in a yeast two-hybrid
screen and has been claimed to serve as an endocytic receptor
for cellular uptake of both PrPC and PrPSc [16,17]. However,
LRP lacks a signal peptide or transmembrane anchor that could
target it to the secretory pathway, and the majority of the
molecules are likely to be cytoplasmic.
Since PrP is a GPI-anchored protein, the entire polypeptide
chain is located on the extracytoplasmic face of the lipid bilayer.Table 1
Putative PrP interactors
Candidate interactor Candidate function Identification
Grb2 Signal transduction
(adaptor protein)
Yeast two-hyb
co-immunopre
Pint1 Unknown Yeast two-hyb
co-immunopre
Synapsin 1b Synaptic vesicle trafficking Yeast two-hyb
co-immunopre
TREK-1 Two-pore K+ channel Yeast two-hyb
co-immunopre
Tubulin Microtubule subunit Cross-linking
NRAGE (Neurotrophin
receptor-interacting
MAGE homologue)
Activator of apoptosis Yeast two-hyb
co-immunopre
Laminin receptor
precursor (LRP)
Extracellular matrix
interactions
Yeast two-hyb
STI-1 (stress-inducible
protein 1)
Heat shock protein Complementa
co-immunopre
Hsp60 Chaperone Yeast two-hyb
N-CAM Cell adhesion Cross-linking
Bcl-2 Multi-domain
anti-apoptotic regulator
Yeast two-hyb
Caveolin-1 Caveolar coat Co-immunoprThus, direct PrP binding partners are most likely to be
transmembrane and secreted proteins. Although PrP potentially
exists as two transmembrane variants (NtmPrP and CtmPrP) that
could theoretically interact with cytoplasmic partners [18,19],
these forms are normally present in minute amounts in the
absence of predisposing mutations in the PrP molecule [18]. PrP
molecules that lie entirely in the cytoplasm have also been
described in cultured cells [20], but our own data indicate that
these forms are likely to be artifacts of over-expression or
treatment with proteasome inhibitors [21]. Of course, PrP could
associate with cytoplasmic proteins indirectly, via involvement
of intermediary proteins that serve as transmembrane linkers.
4. Anti-apoptotic activity of PrP
Several intriguing lines of evidence have emerged recently
suggesting that PrPC may exert a cytoprotective activity,
particularly against internal or environmental stresses that
initiate an apoptotic program (reviewed in [22,23]). This
activity has been demonstrated in a variety of experimental
systems, including cultured mammalian cells, yeast, and mice.
4.1. Cultured cells
One of the clearest examples of a cytoprotective activity of
PrPC is the protein's ability to protect human fetal neurons in
culture against apoptosis induced by Bax. Bax is a pro-apoptotic
member of the Bcl-2 family that plays a major role in
postmitotic neurons of the central nervous system [24,25].
When human fetal neurons in culture were microinjected with a
plasmid encoding Bax, ∼90% of the neurons underwent
apoptosis; but when the neurons were co-injected with both
Bax- and PrP-encoding plasmids, the percentage of apoptotic
cells was reduced to ∼10% [26,27]. This cytoprotective effectmethod Localization Reference
rid;
cipitation
Cytoplasm [101]
rid;
cipitation
Cytoplasm [101]
rid;
cipitation
Cytoplasm (synaptic vesicles) [101]
rid;
cipitation
Plasma membrane
(transmembrane)
[169]
Cytoplasm (cytoskeleton) [170]
rid;
cipitation
Cytoplasm [171]
rid Cytoplasm; Plasma membrane? [16]
ry hydropathy;
cipitation
Cytoplasm; Plasma membrane? [107]
rid Cytoplasm [172]
Plasma membrane (transmembrane
and GPI-anchored forms)
[144]
rid Cytoplasm (mitochondria, ER) [173]
ecipitation Plasma membrane (hairpin loop) [103]
631L. Westergard et al. / Biochimica et Biophysica Acta 1772 (2007) 629–644of PrP appeared to be specific for Bax, since PrP did not prevent
neuronal apoptosis induced by Bak, t-Bid, staurosporine, or
thapsigargin [28].
It has also been reported that expression of PrPC rescued
immortalized hippocampal neurons (HpL3–4 cells) derived
from Prn-p0/0 mice from apoptosis induced by serum depriva-
tion [29,30]. This effect appeared to involve a Bax-mediated
apoptotic pathway.
Another system involves MCF-7 cells, which are derived
from a human mammary adenocarcinoma and undergo
apoptosis in response to treatment with the cytokine, tumor
necrosis factor (TNF-α). Diarra-Mehrpour et al. [31] isolated a
variant sub-clone of MCF-7 cells that was resistant to TNF-α-
induced apoptosis, and found that this clone displayed a
dramatic up-regulation of endogenous PrP gene expression.
Moreover, over-expression of PrPC in the parent MCF-7 line
was sufficient to render it resistant to TNF-α-induced cell death.
At least part of the protective effect of PrPC involved
suppression of a mitochondria-dependent death pathway.
PrP has also been found to rescue cultured cerebellar
granule neurons [32] and N2a neuroblastoma cells [33] from
apoptosis induced by Dpl. Dpl is a PrP paralog which causes
a neurodegenerative phenotype when ectopically expressed
in the CNS of Prn-p0/0 transgenic mice (see Section 4.3). In
N2a cells, it was claimed that the protective effect involvedFig. 1. Possible mechanisms for PrP suppression of Bax-induced apoptosis. PrPC may
direct interaction between the two proteins or by involvement of additional, inter
transmembrane receptor, initiating a signal transduction cascade that culminates
oligomerization (A). Cytoplasmic forms of PrP may produce similar effects via a direc
or enhance an interaction between Bax and anti-apoptotic, multi-domain proteins su
pathway, such as cytochrome c (cyto. c) release, or activation of Apaf-1 and caspases
intracellular calcium and the unfolded protein response (UPR) (F).a physical interaction between PrP and Dpl on the cell
membrane.
In a recently published study, it was reported that PrPC
promoted self-renewal of hematopoietic stem cells during serial
transplantation [34]. This phenomenon could also relate to the
cytoprotective activities of PrPC, since serial transplantation is
likely to subject cells to apoptotic stress. In what could be a
related effect, it was recently reported that PrPC positively
regulates proliferation and differentiation of neural precursor
cells in vitro and in vivo [35].
While these diverse model systems suggest a common
mechanism for PrP cytoprotection, the specific cellular and
molecular pathways involved remain largely unknown. Since
Bax-dependent apoptosis is a common theme in several of these
systems, one possibility is that PrP acts by inhibiting Bax-
mediated cell death. Fig. 1 illustrates several possible mechan-
isms by which this might occur, based on known pathways for
Bax action [24,36]. First, GPI-anchored PrP on the cell surface
might interact with a putative transmembrane receptor, thereby
initiating a signal transduction cascade. This cascade might then
alter Bax activity directly, for example by inhibiting its
mitochondrial translocation, conformational change, or oligo-
merization (Fig. 1A). These same effects might also result from
a physical interaction between Bax and cytoplasmic forms of
PrP (Fig. 1B). Alternatively, a PrP-dependent signal might actinhibit Bax-mediated apoptotic pathways at several different points, either by a
mediary proteins. PrPC on the cell surface (GPI-PrP) may bind to a putative
in inhibition of Bax mitochondrial translocation, conformational change, or
t interaction with Bax (B). PrP may inhibit pro-apoptotic, BH3-only proteins (C),
ch as Bcl-2 and Bcl-XL (D). PrP may suppress downstream events in the Bax
(E). Finally, PrP in the ER may alter Bax function in this organelle, via effects on
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BH3-only activators of Bax (Fig. 1C), or enhanced association
of Bax with anti-apoptotic regulators such as Bcl-2 or Bcl-XL
(Fig. 1D). It is also possible that PrP suppresses downstream
effects of Bax, such as release of cytochrome c, or activation
of Apaf-1 and caspases (Fig. 1E). Finally, since Bax is known
to have effects on calcium release and the unfolded protein
response (UPR) in the ER, [37,38], PrP traversing the
secretory pathway could also affect Bax activity associated
with this organelle, possibly via a transmembrane receptor
(Fig. 1F).
At this point, there is a dearth of experimental data to
distinguish among the different mechanisms outlined in Fig. 1.
A recent study of the Bax suppressive effects of PrPC utilizing
several different cell types (fetal neurons, HpL3–4 cells, MCF-7
cells) concluded that PrP inhibits the conformational change
that occurs when Bax is activated and targeted to the outer
mitochondrial membrane [28]. This result would be consistent
with mechanisms A and B in Fig. 1. Mechanism B is also
suggested by a study showing that an engineered form of
cytoplasmic PrP protects fetal neurons against Bax [27].
However, other studies have shown that cytoplasmic PrP
produces a toxic rather than protective effect by binding to and
sequestering Bcl-2 [39]. In any event, the physiological
significance of cytoplasmic PrP is uncertain at this point,
since very little of this form appears to be generated in vivo from
the wild-type molecule [40] Clearly, further progress in
elucidating the mechanism underlying PrP cytoprotection will
require identification of other proteins that interact physically
and functionally with PrP and connect it to cell death and
survival pathways.
4.2. Yeast
In order to investigate the anti-apoptotic effect of PrP in a
genetically tractable experimental system, we have recently
turned to baker's yeast, Saccharomyces cerevisiae. Extensive
work by other laboratories has shown that heterologous
expression of mammalian Bax in yeast is lethal [41]. Although
S. cerevisiae does not contain endogenous Bcl-2 family
members or caspases, the initial events underlying Bax activity
in yeast and mammalian cells are similar, including transloca-
tion of the protein to mitochondria, release of cytochrome c, and
alterations in mitochondrial function [41,42].
We have found that expression of mammalian PrP in yeast
efficiently suppresses cell death induced by Bax [43]. Our assay
system utilizes yeast expressing mammalian Bax from a
galactose-inducible promoter (GAL10). The yeast also consti-
tutively express a form of PrP containing a modified signal
peptide that we have shown to be targeted to the secretory
pathway [44]. The assay involves comparing growth of the
yeast on glucose vs. galactose medium. The basic effect is
shown in Fig. 2A, B, which demonstrates that Bax-expressing
yeast transformed with the PrP plasmid grow well on galactose
medium, while Bax-expressing yeast transformed with the
vector plasmid fail to grow on galactose. In contrast, both stains
of yeast grow well on glucose medium, which does not inducesynthesis of Bax. Fig. 2C demonstrates that PrP does not alter
expression levels of Bax, ruling out a trivial explanation for PrP
rescue activity. We have carried out a detailed structure–
function analysis to define which domains of the PrP molecule
are necessary for the Bax protective effect (Fig. 2D). We are
currently using this yeast system to perform screens aimed at
identifying genes that are essential for PrP rescue activity, and to
characterize the cellular mechanisms involved.
The ability of PrP to rescue yeast from Bax-induced death
has been confirmed by Bounhar et al. [45] using dye exclusion
and colony-forming ability as measures of cell viability. In
contrast to us, however, these authors found that non-secreted
(cytoplasmic) forms of PrP possessed rescue activity, since
neither of the two PrP constructs they analyzed entered the
secretory pathway to any significant extent. They also reported
that PrP failed to prevent growth inhibition caused by Bax,
although PrP expression did have effects on the yeast cell cycle
as monitored by flow cytometry.
4.3. Mice
Two kinds of mouse models dramatically exemplify a
cytoprotective activity of PrPC in vivo. In one model,
Shmerling et al. [46] expressed a series of N-terminally deleted
forms of PrP in transgenic mice. Deletions encompassing
residues 32 through 106 did not cause any abnormalities, but
two larger deletions (Δ32–121 or Δ32–134, collectively
referred to PrPΔN) caused a progressive neurodegenerative
illness in mice lacking both copies of the endogenous PrP gene
(Prn-p). Strikingly, a single Prn-p allele was sufficient to
completely abrogate the phenotype of these animals. A similar
phenomenon was described in certain Prn-p0/0 mouse lines in
which the prion-like protein Dpl was ectopically expressed in
the brain as a result of intergenic splicing events between the
adjacent PrP and Dpl genes [47–50]. Dpl is structurally similar
to PrPΔN, since it lacks regions homologous to the flexible, N-
terminal tail of PrP. Re-introduction of wild-type PrP also
rescued Dpl-expressing mice from neurodegenerative illness
[49,51–53].
We have recently documented an analogous rescue effect in
Tg(Δ105–125) mice that express PrP harboring a deletion of
residues 105–125 [54]. These mice spontaneously develop a
severe neurodegenerative illness that is lethal within 1 week of
birth in the absence of endogenous PrP. This phenotype is
reversed in a dose-dependent fashion by co-expression of wild-
type PrP, with 5-fold over-expression delaying death beyond 1
year. Thus, the phenotype of Tg(PrPΔ105–125) mice is
reminiscent of, but much more severe than, those described in
mice that express PrPΔN and Dpl. The fact that PrP suppresses
the phenotypes induced by PrPΔN, PrPΔ105–125 and Dpl
suggests that a common mechanism facilitates the protective
effect of PrP against each of these toxic proteins. We have
speculated that the greatly enhanced toxicity of PrPΔ105–125,
coupled with the requirement for supraphysiological levels of
wild-type PrP to rescue the neurodegenerative phenotype, is due
to increased affinity of PrPΔ105–125 for a hypothetical
receptor that transduces the toxic signal [54].
Fig. 2. PrP targeted to the secretory pathway protects yeast against Bax-induced cell death. (A) S. cerevisiae expressing Bax from a galactose-inducible promoter were
transformed with empty vector, or with vector constitutively expressing either PrP or human Bax-inhibitor 1 (BI-1) (a positive control protein). The PrP construct was
engineered to allow expression in the secretory pathway [44]. Three independent transformants (a–c) were spotted in serial 5-fold dilutions (left to right) on glucose or
galactose plates and allowed to grow for 3 or 6 days, respectively. Co-expression of PrP allows yeast to grow on galactose medium (i.e., under conditions where Bax
synthesis is induced). (B) Quantitation of the protective effects of PrP and BI-1. Yeast transformed as in (A) were plated onto glucose or galactose plates, and the
number of colonies counted. Results are expressed as the number of colonies on the galactose plates as a % of those on the glucose plates. PrP is even more potent than
BI-1 in restoring growth in the presence of Bax. (C) Lysates prepared from three independent yeast transformants (as described in A) were subjected to Western
blotting using anti-PrP (upper panel, lanes 1–7), anti-HA to detect BI-1 (upper panel, lanes 8–10), or anti-Bax (lower panel, lanes 1–10). Lane 1 shows yeast that carry
the empty vectors used for Bax and PrP/BI-1 expression. Neither PrP nor BI-1 affect expression levels of Bax. (D) Deletion analysis to determine which domains of
PrP are required for its ability to protect yeast from Bax-induced cell death. Yeast expressing Bax from a galactose-inducible promoter were transformed with plasmids
encoding wild-type (WT) PrP, or the indicated deletion constructs. Growth on glucose and galactose plates was assessed as in panels A and B in order to score PrP
rescue activity. The green boxes indicate the hybrid signal sequence used to target PrP to the secretory pathway [44], and the blue boxes indicate the octapeptide
repeats. Data are from Li and Harris [43].
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mammalian cells and mice
It is instructive to compare the sequence domains of PrP that are
essential for its cytoprotective activity in yeast, cultured mam-
malian cells, and mice. Such comparisons suggest a number of
similarities between these three systems, as well as a few diffe-
rences (Table 2). Thus, this cytoprotective function of PrPC appears
to be partially but not completely conserved throughout evolution.
The first region of importance (residues 23–31; KKRPKPG-
GW in mouse) lies at the extreme N-terminus of PrP and includes
four positively charged residues. This segment is known to play a
role in endocytic trafficking of PrP [14,55] and in localization of
the protein to lipid rafts [56]. This region has been found to be
essential for PrP protection against Bax in yeast [43] and Dpl in
cerebellar granule neurons [32]. In transgenic mice, deletions
beginning at residue 32 (PrPΔ32–80 and PrPΔ32–93) do notaffect the ability of PrP to suppress neurodegeneration induced by
PrPΔN [46] (Li et al., manuscript in preparation). In contrast,
deletion of residues 23–88 obliterates the ability of PrP to rescue
mice fromDpl-induced toxicity [57]. The latter two results together
implicate residues 23–31 in protection against PrPΔN and Dpl,
although generation of Tg(PrPΔ23–31) mice will be necessary to
confirm this inference. The requirement for residues 23–31
suggests that PrP cytoprotective activity may depend on localiza-
tion to the cell surface, lipid rafts, or endosomal compartments.
Another domain that has been tested is the C-terminal,
GPI addition signal. In both yeast [43] and human neurons
[26], deletion of this region does not impair the ability of
PrP to suppress Bax-mediated apoptosis, implying that PrP
cytoprotective activity does not require tethering to the plasma
membrane. Similarly, PrP rescue of granule neurons from Dpl-
induced apoptosis does not require the GPI anchor [32]. To
determine whether these observations in yeast and cultured
Table 2
Structure–activity relationships for PrP cytoprotection in yeast, mammalian cells, and mice
PrP molecule Yeast Mammalian cells Mice
Rescue from Bax Rescue Toxic stimulus/cell type Rescue Toxic stimulus
Wild-type PrP + [43,45] + Bax/human fetal neurons [26] + PrPΔN [46]
+ Serum deprivation/immortalized
hippocampal neurons [29]
+ Doppel [49,52,53]
+ Doppel/cerebellar granule neurons [32] + PrPΔ105–125 [54]
Δ23–31 − (Δ23–31) [43] − (Δ23–28) Doppel/cerebellar granule neurons [32] − (Δ23–88) Doppel [57]
+ (Δ32–80/93) PrPΔN [46]
Δ octarepeats + [43] − Bax/human fetal neurons [26] + (Δ32–93) PrPΔN [46]
− Serum deprivation/immortalized
hippocampal neurons [60]
− Doppel/cerebellar granule neurons [32]
GPI− + [43] + Bax/human fetal neurons [26] ND
+ Doppel/cerebellar granule neurons [32]
Cytoplasmic PrP (23–231) − [43] + Bax/human fetal neurons [27] ND
D178N + [43] − Bax/human fetal neurons [26] ND
E199K + [43] ND + Doppel [57]
PG14 − [43] ND +/− PrPΔN (Li et al.,
manuscript
in preparation)
ND, not determined.
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anchorless PrP [58] could be crossed with mice expressing
PrPΔN or Doppel. The lack of requirement for the GPI anchor
suggests that the cytoprotective activity of PrP does not involve
signal transduction through the PrP molecule itself, but perhaps
through a transmembrane protein to which PrP binds on the
extracellular surface.
A related issue concerns the necessity for expression of PrP in
the secretory pathway. In our experiments, deletion of the N- and
C-terminal signal peptides (PrP23–231) completely abolishes
the ability of PrP to rescue yeast from Bax-induced cell death
[43]. This result indicates that PrP must be targeted to the se-
cretory pathway to be active in yeast, and also makes it unlikely
that PrP interacts directly with cytosolic Bax (mechanism B in
Fig. 1). In contrast, PrP23–231 retains full rescue activity
against Bax in cultured human neurons [27]. Whether this
discrepancy implies a fundamental difference in the cytoprotec-
tive pathways operative in yeast andmammalian cells remains to
be determined. The protective activity of cytoplasmic PrP in
human neurons is surprising, since in other cultured cell types
and in transgenic mice cytoplasmic PrP is toxic [39,59].
The role of the PrP octapeptide repeats has also been
analyzed in several systems. The repeats are known to bind
copper ions, which have been postulated to play a role in the
function of PrPC (see Section 6). Deletion of the octapeptide
repeats abolishes the ability of PrP to protect cortical neurons
from Bax [26], granule neurons from Doppel [32], and
immortalized hippocampal neurons from serum deprivation
[60]. In contrast, removal of the repeats does not affect the
ability of PrP to protect yeast from Bax [43] or transgenic mice
from PrPΔN [46]. These observations are difficult to reconcile,
perhaps because the octapeptide repeats perform distinctfunctions in different cell types or in the context of different
toxic insults.
Another interesting point of comparison concerns the effect of
disease-causing mutations on the rescuing activity of PrP. D178N
and E199K mutants retain the ability to rescue yeast from Bax-
mediated cell death [43]. In contrast, PG14, a mutant harboring
an insertion of nine additional octapeptide repeats, lacks rescue
activity [43]. Biochemical analysis of these mutant proteins
suggests that the loss of protective activity of PG14may be due to
its aggregated state, whereas D178N and E199K are completely
soluble in yeast. This observation is consistent with studies in
transgenic mice, since PG14 PrP is aggregated when expressed in
the brain [61] and is also partially deficient in its ability to
suppress the neurotoxicity of PrPΔ32–134 (Li et al., manuscript
in preparation). PrP carrying the E199K mutation, which has
been shown to be completely soluble in mouse models [62],
maintains the ability to suppress Doppel-induced neurodegenera-
tion [57]. Although soluble in yeast, D178N PrP is partially
detergent resistant in cultured neurons [63], which may explain
the inability of this mutant to rescue neurons from Bax [26].
Taken together, these results indicate that the cytoprotective
activity of PrP requires a soluble form of the protein, and that
mutations inducing aggregation impair activity.
5. PrPC and oxidative stress
A frequently discussed hypothesis to explain the pathogen-
esis of several neurodegenerative disorders involves chronic
oxidative stress. Dysfunction of any of several interconnected
cellular pathways is sufficient to cause oxidative stress in the
brain, including impaired mitochondrial function, increased
oxidative damage, defects in the ubiquitin–proteasome system,
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lism, excitotoxicity, and inflammation (reviewed in [64]).
Several lines of evidence suggest that PrPC may play a role
in protecting cells from oxidative stress (reviewed in [65]).
Perhaps the most compelling observation is that neurons
(cerebellar granular and neocortical) cultured from Prn-p0/0
mice are more susceptible than neurons from wild-type mice to
treatments with agents that induce oxidative stress, including
hydrogen peroxide, xanthine oxidase and copper ions [66,67].
Consistent with these cell culture results, brain tissue from
Prn-p0/0 mice exhibits biochemical changes indicative of
oxidative stress, such as increased levels of protein carbonyls
and lipid peroxidation products [68]. In addition, brain lesions
induced by hypoxia and ischemia are larger in Prn-p0/0
compared to Prn-p+/+ mice [69–71]. Since hypoxia and
ischemia probably cause neuronal death via oxidative damage,
these observations also tie PrPC to protection from oxidative
stress.
How might PrPC protect cells from oxidative stress? One
possibility is that PrPC itself acts directly to detoxify reactive
oxygen species (ROS). Consistent with this idea, it has been
claimed that PrPC (both recombinant, and immunoprecipitated
from brain tissue or cultured cells) displays a copper-dependent
superoxide dismutase (SOD) activity [72,73]. However, the
biological significance of these results is questionable for
several reasons. First, the SOD activity measured for recombi-
nant PrP depended on refolding the protein from a denatured
state in the presence of supra-physiological concentrations of
copper. Second, even small organic molecules like amino acids
can bind copper and exhibit weak dismutase activity. Finally,
copper binds much more weakly to PrPC than to known
cuproenzymes like Cu–Zn SOD [74], arguing against the
possibility that the copper plays a specific catalytic role in PrPC.
In a recent report, Jones et al. [75] failed to detect SOD activity
above background levels in recombinant PrP refolded from a
denatured state in the presence of excess copper (as in the
original studies of Brown and colleagues), or in PrP loaded with
copper after folding.
A second hypothesis is that PrPC acts indirectly to protect
cells from oxidative stress by up-regulating the activities of
other proteins, such as Cu–Zn SOD, that detoxify ROS. It has
been reported that the enzymatic activity and the 64Cu loading
of Cu–Zn SOD from the brains of Prn-p0/0 mice is 10–50% of
normal [66,76,77]. Moreover, it has been claimed that the
activity and copper loading of Cu–Zn SOD are increased in
PrP-over-expressing mice. However, we [78] and others [79]
have been unable to replicate these results. The activities of
other anti-oxidant enzymes such as catalase and glutathione
reductase have been reported to be decreased in Prn-p0/0 mice
[77,80], but whether PrPC plays a direct role in regulating these
molecules remains to be determined.
It is also possible that PrPC acts either upstream or
downstream of ROS to protect cells from oxidative stress. In
some situations, for example, oxidative stress may activate
apoptotic pathways [64]. In such cases, the anti-apoptotic
effects of PrPC described in Section 4 may account for the
protein's ability to protect cells against oxidative stress.6. PrPC and copper
Copper is an essential cofactor for a number of enzymes that
catalyze redox reactions. Because ionic copper is highly
reactive, however, cells have evolved specialized mechanisms
for its uptake and transport [81]. Defects in copper metabolism
have been linked to a number of human diseases, including
several neurodegenerative disorders [82]. An extensive body of
evidence has accumulated suggesting a connection between
PrPC and copper ions (reviewed in [83,84]).
The most widely agreed upon observation is that PrPC is a
copper-binding protein [85–88]. The histidine-containing
octapeptide repeats specifically bind up to four Cu2+ ions
copper in a pH-dependent and negatively cooperative manner,
with an affinity that may be as high as 0.1 nanomolar
(depending on binding site occupancy) [89]. Binding involves
coordination with nitrogen atoms in the imidazole side chains of
histidine residues, as well as with nitrogen and oxygen atoms in
main-chain amide linkages involving glycine residues. Two
additional copper binding sites exist at residues 96 and 111 [90].
Copper binding has been shown to cause conformational
changes in the flexible, N-terminal tail of PrP [91,92].
Copper ions also alter the biochemical and cell biological
properties of PrPC. Copper causes PrPC in brain homogenates to
assume an aggregated and protease-resistant form that is distinct
from PrPSc [93]. In addition, micromolar concentrations of
copper stimulate endocytosis of cell-surface PrP via clathrin-
coated pits [94–96]. This effect requires binding of copper to
the octapeptide repeats, and exit of PrP from lipid raft domains
[55]. Based on the effects of copper on PrP trafficking, we have
hypothesized that the protein serves as a receptor for cellular
uptake or efflux of copper ions [94]. It is also possible that PrPC
acts as a sink for binding of copper ions at the cell surface
without actually undergoing endocytosis.
One piece of evidence that would strongly support a role for
PrPC in copper uptake or efflux would be a correlation between
PrPC expression levels and the copper content of cells or tissues.
An initial report indicated that the content of copper, but not of
several other transition metals, is only 10% of normal in crude
membranes, synaptosomes, and endosomes derived from the
brains of Prn-p0/0 mice [85]. A subsequent study from the same
authors [97] reported that synaptosomes from Prn-p0/0 mice
had a copper content that was 50% of the wild-type level, a
considerably smaller difference than in the original report.
Based on these results, the authors proposed that PrPC may play
a role in regulating copper release at the synapse [98].
We have re-examined this subject by using mass spectro-
metry to measure the concentrations of several transition metals
in brain tissue from wild-type and Prn-p0/0 mice, as well as in
Tga20 mice that over-express PrP by 10-fold. We were unable
to find any differences in metal content in either whole brain or
of several subcellular fractions among mice of these three
genotypes [78], and we believe that the results of Brown and
colleagues are likely to be in error.
We have also utilized yeast as an experimental system to test
the role of PrPC in copper metabolism [44]. Much of what we
know about cellular utilization of copper ions in eukaryotes is
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the effect of PrP expression on the growth phenotypes of yeast
strains harboring deletions of genes that encode key compo-
nents of copper utilization pathways, including transporters,
chaperones, pumps, reductases, and cuproenzymes. We failed to
find an effect of PrP expression on the growth deficiency of any
of the yeast strains tested.
Taken together, these studies in yeast and mammalian
systems suggest that PrPC is unlikely to be part of a major
pathway for copper uptake or efflux by cells and tissues. Of
course, the results do not rule out involvement of PrPC in more
specialized processes for metabolism or trafficking of this metal
ion. Additionally, copper binding may play a regulatory role by
modulating the physiological activity of PrPC.
7. PrPC and transmembrane signaling
Since most PrPC is localized to the cell surface, it is
reasonable to hypothesize that the protein could participate in
transmembrane signaling processes. Like other GPI-anchored
proteins, PrPC resides in lipid raft domains on the plasma
membrane, which are known to serve as molecular scaffolds for
signal transduction [99,100]. Since its polypeptide chain is
entirely extracellular, PrPC would presumably need to interact
with transmembrane adaptor proteins in order to transmit
signals into the cytoplasm. Yeast two-hybrid screens have
identified several signaling molecules that bind to PrP,
including Grb2 and synapsin 1b [101]. However, because
these molecules are cytoplasmic, they are unlikely to directly
associate with membrane-bound PrPC in a cellular environment.
Clearly, a crucial challenge in the field is to identify the
molecular components of putative PrPC-mediated signal
transduction pathways.
There are now a number of studies suggesting that PrPC can
activate transmembrane signaling pathways involved in several
different phenomena, including neuronal survival, neurite
outgrowth, and neurotoxicity. In some of these cases, signal
transduction is initiated by interaction of PrPC with specific
protein or peptide ligands. In other cases, PrPC appears to act
constitutively.
An artificial situation in which PrPC-mediated signaling has
been observed involves antibody-induced cross-linking of cell-
surface PrPC. Presumably, the antibodies in this type of
experiment are mimicking the action of naturally occurring
PrPC ligands. Antibody-induced cross-linking of GPI-anchored
proteins on the cell surface is a technique commonly used to
activate phosphorylation-dependent signaling cascades in
lymphocytes [102]. Similarly, antibody-mediated cross-linking
of PrPC on a neuroectodermal cell line (1C11) was found to
stimulate the activity of the non-receptor tyrosine kinase, fyn
[103]. This effect was reported to require interaction of PrPC
with the raft protein caveolin. In a subsequent study, it was
shown that antibody-induced fyn activation in 1C11 cells led to
downstream stimulation of NADPH oxidase and extracellular-
regulated kinases (ERKs), as well as production of reactive
oxygen species [104]. The activities of several G protein-
coupled serotonin receptors found on the surface of these cellswere also altered by PrP cross-linking [105]. The signaling
pathways engaged by anti-PrP antibodies in 1C11 cells are
postulated to have pro-survival effects [104].
Another kind of pro-survival signaling pathway that has been
characterized involves an interaction between PrPC and stress-
inducible protein 1 (STI-1). STI-1 was originally described as a
co-chaperone found in macromolecular complexes with heat
shock proteins of the Hsp70 and Hsp90 families [106].
Although STI-1 lacks a signal sequence and is primarily
localized to the cytoplasm and nucleus, some molecules have
been reported to reside on the plasma membrane and to co-
immunoprecipitate with PrPC [107]. Interaction with cell
surface STI-1 has been proposed to mediate PrPC-dependent
protection of retinal explants from anisomycin-mediated cell
death [107]. This effect was found to depend on activation of a
cAMP/protein kinase A pathway [108]. A recent study also
demonstrated that incubation of cultured hippocampal neurons
with recombinant STI-1 stimulated neurite outgrowth in a PrP-
dependent manner, an effect requiring signaling through a
mitogen-activated protein kinase (MAPK) pathway [109].
Two recent studies have suggested a potential role for the PI3
kinase/Akt signaling pathway in the neuroprotective effects of
PrPC. In one study [110], infarct volumes were measured in
Prn-p+/+ and Prn-p0/0 mice that had been subjected to focal
cerebral ischemia. It was found that Prn-p0/0 mice displayed
significantly larger infarct volumes, demonstrating a protective
role for PrPC in response to brain injury. Additionally, the level
of phosphorylated Akt was diminished in Prn-p0/0 mice,
indicating that PrPC may enhance Akt-dependent cell survival
pathways to prevent damage inflicted by ischemic brain injury.
In a second study [111], Akt activity was found to be diminished
in neurons and brain tissue from Prn-p0/0 mice compared to
Prn-p+/+ mice. Moreover, it was reported that pharmacological
inhibition of Akt reduced the ability of PrPC to protect cells
against oxidative damage.
Another context in which PrPC-mediated signal transduction
events have been observed involves neurite outgrowth. Cell
surface PrPC facilitates axonal outgrowth via cis and trans
interactions with N-CAM, a process that involves recruitment of
N-CAM to lipid rafts and activation of fyn kinase [112].
Treatment of cultured neurons with recombinant PrP also
enhances neurite outgrowth and neuronal survival, concomitant
with activation of several kinases, including fyn, PKC, PKA,
PI-3 kinase/Akt, and ERK [113,114].
The signaling processes described thus far involve positive
effects of PrPC on neuronal survival or differentiation.
However, there is also evidence that PrPC can mediate
neurotoxic effects via activation of specific signaling cascades.
One example involves the synthetic peptide PrP106–126,
which displays certain biochemical properties of PrPSc and
has been used to mimic the effects of PrPSc on cultured cells
[115]. PrP106–126 is toxic to cultured neurons and neuronal
cell lines, but only those that express PrPC, suggesting that the
toxic action is mediated by a PrPC-dependent signaling pathway
[116,117]. Consistent with this idea, PrP106–126 has been
reported to stimulate a number of intracellular kinase cascades,
including those involving p38, ERK1/2, and JNK1/2 [118–
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PrPC expression has been reported to sensitize neurons and
neuronal cell lines to the apoptotic action of the kinase inhibitor,
staurosporine [121–123]. This effect required endocytosis of
PrPC, and was mediated by increased activity of the key
transcriptional regulator p53.
8. A role for PrPC at synapses
Several experimental observations suggest that PrPC could
play a role in synaptic structure, function or maintenance. This
hypothesis is consistent with the fact that synaptic pathology is
often a prominent feature of prion diseases [124]. Light and
electron microscopic immunocytochemical studies, as well as
localization of a PrP–EGFP fusion protein, indicate that PrPC is
preferentially concentrated along axons and in pre-synaptic
terminals [125–130]. In addition, PrPC is subject to anterograde
and retrograde axonal transport [131,132], and PrP–EGFP
fusion proteins can be visualized in what appear to be axonally
transported synaptic vesicles (Medrano and Harris, unpublished
observations). Incubation of cultured hippocampal neurons with
recombinant PrP induces rapid elaboration of axons and
dendrites, and increases the number of synaptic contacts
[113]. This result suggests that PrPC could play a regulatory
role in synapse formation. There is evidence that PrPC could
serve a function at peripheral as well as central synapses. It was
reported that PrPC is concentrated at the neuromuscular junction
where it is localized in the sub-synaptic sarcoplasm, possibly
associated with endosomal structures [133]. In addition,
nanomolar concentrations of recombinant PrP have been
found to potentiate acetylcholine release at the neuromuscular
junction [134].
Electrophysiological recordings from brain slices of Prn-p0/0
mice also support a functional role for PrP in synaptic
transmission. In hippocampal slices from Prn-p0/0 mice, it
was initially reported that long term potentiation was impaired
and receptor-mediated fast inhibition involving GABA-A
receptors was decreased [135,136]. However, this result was
subsequently disputed [137]. More recent studies have
demonstrated a positive correlation between the expression
level of PrPC and the overall strength of glutamatergic
transmission in the hippocampus, with PrP-over-expressing
mice exhibiting supra-physiological responses [138]. At least
part of this effect seemed to result from more efficient
recruitment of pre-synaptic fibers as the level of PrPC
increased. Correlating with reduced after-hyperpolarization
seen in hippocampal CA1 neurons of Prn-p0/0 mice [139],
cerebellar Purkinje cells from these animals have been
reported to show decreased Ca2+-activated K+ currents
[140]. Reduced after-hyperpolarization was observed in
pyramidal neurons regardless of whether the PrP gene was
deleted pre- or postnatally [3].
Prn-p0/0 mice have been reported to display several other
neurobiological abnormalities that may also relate to the
participation of PrPC in synapse formation and function.
These include alterations in nerve fiber organization [141],
circadian rhythm [142], and spatial learning [143].9. PrPC and cell adhesion
PrPC has been found to interact with several proteins
involved in cell adhesion. For example, cross-linking
experiments have identified a binding interaction between
PrP and neural cell adhesion molecule (N-CAM) [144]. In
cultured hippocampal neurons, this interaction results in
redistribution of N-CAM to lipid rafts, activation of fyn
kinase, and enhancement of neurite outgrowth [112].
Laminin, a major structural component of basement mem-
branes, has also been shown to be a binding partner of PrPC.
In neurons, laminin plays a significant role in cell prolifera-
tion, supports neurite outgrowth, and aids in cellular migra-
tion. Graner et al. [145] have shown that PrP binding to
laminin promotes neurite outgrowth in PC12 cells and
hippocampal neurons. Laser ablation of cell-surface PrP
caused retraction of neurites [146]. Finally, expression of
PrP has been found to enhance aggregation of neuroblastoma
cells, although the molecular mechanisms underlying this
phenomenon are uncertain [147].
10. Prion pathogenesis may involve alterations in the
physiological function of PrPC
A great deal of effort in the prion field has been devoted to
understanding of the chemical nature of the infectious agent,
and testing the validity of the protein-only mechanism of
infectivity. In contrast, much less attention has been paid to the
question of how PrPSc or other abnormal forms of PrP cause
CNS pathology. It is now becoming clear, however, that prions
may kill nerve cells by virtue of their ability to perturb the
normal, physiological activities of PrPC. In this section, we will
outline three different hypotheses explaining how changes in
PrPC function can cause neurodegeneration (reviewed in
[148,149]).
10.1. Gain of function
The most widely discussed hypothesis is that prion
pathology is attributable to a toxic gain-of-function mechanism
(Fig. 3A). In this view, PrPSc possesses novel toxic properties
that are not related to the normal, physiological function of
PrPC. For example, aggregates of PrPSc may block axonal
transport, interfere with synaptic function, or trigger apoptotic
pathways.
10.2. Loss of function
An alternative hypothesis for prion toxicity postulates that
PrPC possesses a biological activity that is lost upon conversion
to or contact with PrPSc (Fig. 3B). Loss of this putative PrPC
function would then cause neurodegeneration. In principle, loss
of any of several of the putative functions of PrPC discussed
above could produce pathogenic consequences. However, the
anti-apoptotic activity of PrPC (Section 4) is most easily
accommodated in such a mechanism, since loss of this activity
could lead directly to neuronal death.
Fig. 3. Models for the cellular toxicity of PrPSc. (A) Toxic gain-of-function
mechanism. PrPSc (or PrPtoxic, a pathogenic intermediate) possesses a novel
neurotoxic activity that is independent of the normal function of PrPC. (B) Loss-
of-function mechanism. PrPC possesses a normal, physiological activity, in this
case neuroprotection, that is lost upon conversion to PrPSc. (C) Subversion-of-
function mechanism. The normal, neuroprotective activity of PrPC is subverted
by binding to PrPSc (or PrPtoxic). Cross-hatching of the rectangle representing
PrPC indicates a change in its signaling properties such that a neurotoxic rather
than a neuroprotective signal is delivered. Taken from Harris and True [148].
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function mechanism in prion diseases. First, genetic ablation of
PrP expression, either prenatally [1,2] or postnatally [3], has
relatively little phenotypic effect, and does not produce any
features of a prion disease. Thus, loss of PrPC function cannot,
by itself, account for prion-induced neurodegeneration. How-
ever, it is possible that a loss-of-function mechanism exacer-
bates pathology caused by toxic gain of function or other
mechanisms. For example, a cytoprotective activity of PrPC that
is dispensable under normal conditions may become essential in
the disease state due to cellular or organismal stress. Loss of
PrPC function as a pathogenic mechanism also appears to be
incompatible with the dominant mode of inheritance of familial
prion diseases. In this regard, however, PrPSc or mutant PrP may
sequester wild-type PrPC into aggregates that lack functional
activity, thereby producing a dominant-negative effect.
A consideration which argues for a loss rather than a gain of
function in some familial prion diseases relates to the effect of
PrP mutations on the thermodynamic stability and biochemical
properties of PrP. Although some mutations markedly destabi-
lize the protein, favoring misfolding and formation of PrPSc-like
aggregates, others do not [150,151]. It is difficult to explain the
pathogenicity of the latter mutants on the basis of the
accumulation of toxic protein aggregates. Rather, it seems
more likely that these proteins are deficient in some functional
property normally displayed by wild-type PrP. Consistent with
this proposal, we have shown that an octapeptide insertional
mutation in PrP partially impairs the cytoprotective activity of
the protein in both a yeast model [43] and a transgenic mouse
model (Li et al., manuscript in preparation).
10.3. Subversion of function
A third possible hypothesis for prion pathogenesis involves a
subversion of the normal neuroprotective function of PrPC (Fig.3C). In this mechanism, interaction with PrPSc converts PrPC
from a transducer of neuroprotective signals into a transducer of
neurotoxic signals. Consistent with this model, there are now a
number of experimental situations in which expression of PrPC
in neurons, rather than being neuroprotective, appears to be
essential for conferring sensitivity to PrP-related neurotoxic
insults. First, Prn-p0/0 neurons are resistant to the toxic effects
of PrPSc supplied from grafted brain tissue [152] or from nearby
astrocytes [153]. Second, scrapie-inoculated mice expressing a
GPI-negative version of PrP develop minimal brain pathology
and neurological dysfunction despite the accumulation of
numerous PrPSc-containing amyloid plaques [58]. This result
implies that PrP must be membrane-anchored to efficiently
transduce a toxic signal. Third, Prn-p0/0 neurons in culture have
been found to be resistant to apoptosis induced by exposure to
the synthetic peptide PrP106–126, which has been used as a
model for PrPSc [117].
How might the neuroprotective activity of PrPC be subverted
to produce a neurotoxic effect? Presumably, a physical
interaction of PrPSc with PrPC is required. One possibility is
that PrPSc induces aggregation of cell surface PrPC, thereby
generating a neurotoxic rather than a neuroprotective signal.
Consistent with this model, cross-linking of PrPC with anti-PrP
antibodies induces apoptosis of CNS neurons in vivo [154].
Alternatively, PrPSc may bind to and block specific regions of
PrPC, thereby altering the signaling properties of the latter.
Support for the latter mechanism comes from Tg(PrPΔ105–
125) mice we have made that express PrP containing a deletion
of a highly conserved block of 21 amino acids in the
unstructured, N-terminal tail of the protein [54] (see Section
4.3). The neurotoxicity of PrPΔ105–125 observed in these
animals suggests a model in which residues 105–125 constitute
a critical binding site for interaction between PrPC and a
hypothetical, cell-surface receptor (designated Tr) that can
transduce either neuroprotective or neurotoxic signals. PrPC
binding to Tr normally elicits a neuroprotective signal, but
deletion of the 105–125 domain of PrPC subverts this
interaction in such a way that a neurotoxic signal is generated.
We speculate that exogenous PrPSc perturbs binding interac-
tions between Tr and the 105–125 domain of PrPC, thereby
producing a neurotoxic effect equivalent to deletion of residues
105–125 [54]. A similar phenomenon might occur with the
synthetic peptide PrP106–126, which is toxic to cultured
neurons in PrPC-dependent fashion [117]. In this scenario, the
neurotoxic pathways activated by PrPSc and PrP106–126 would
be the same as those activated by PrPΔ105–125, PrPΔN and
Dpl. However, wild-type PrPC would have opposite effects in
the two situations: it would suppress the toxicity of PrPΔ105–
125, PrPΔN and Dpl, but it would be required for the toxicity of
PrPSc and PrP106–126.
10.4. Loss of function as a pathogenic mechanism in other
neurodegenerative diseases
Toxic gain of function is commonly invoked to explain the
phenotypes of other dominantly inherited neurodegenerative
disorders including Alzheimer's disease, Huntington's and
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frontotemporal dementia, and amyotrophic lateral sclerosis. In
these disorders, it is postulated that intracellular or extracellular
aggregates of the relevant misfolded protein (Aβ, huntingtin, α-
synuclein, tau, or SOD1) possess a neurotoxic activity that is
not directly related to the normal, physiological function of the
parent protein [155]. However, in at least some of these
disorders, a loss-of-function mechanism similar to what we
have proposed for prion diseases (Section 10.2) may also be
operative. Huntington's and Parkinson's diseases provide
especially clear examples of this idea.
Huntington (Htt), like PrP, has been found to possess
physiological activities that promote neuronal survival, and loss
of these activities may contribute to disease pathogenesis [156].
For example mice lacking Htt show extensive cell death in the
embryonic ectoderm [157]. Moreover, it has been reported that
wild-type Htt up-regulates transcription of BDNF, and that
mutant Htt lacks this activity, leading to compromised neuronal
differentiation and survival [158]. Wild-type Htt may also
facilitate vesicular transport of BDNF along axons [159].
Consistent with a neuroprotective effect of Htt, over-expression
of wild type Htt in transgenic mice significantly reduced the
cellular toxicity elicited by various Htt mutants [160,161].
Similarly, there is evidence that α-synuclein, which
comprises the Lewy bodies of Parkinson's disease, may have
anti-apoptotic activities. Expression of wild type α-synuclein in
primary neurons and neuronal cell lines protects the cells from
death induced by serum deprivation, H2O2-induced oxidative
stress, and glutamate-induced toxicity [162–164]. This protec-
tive effect was not observed with the two disease-associated
mutants of α-synuclein (A30P and A53T) [162].
These results suggest that some of the pathogenic mecha-
nisms operative in prion diseases may be closely related to
those underlying other, more common neurodegenerative
disorders. This idea is consistent with evidence that prion
neurotoxicity is attributable to small, non-infectious PrP
oligomers that are distinct from PrPSc, and that are similar to
the pathogenic aggregates seen in other protein misfolding
disorders [148,165].
11. Conclusions
For many years the PrPSc isoform of the prion protein has
consumed the attention of investigators because of its relation-
ship to infectivity, and its specific accumulation during the
disease process. PrPC, the cellular isoform, was of interest
primarily because it served as a necessary precursor to PrPSc,
but its intrinsic physiological function seemed irrelevant to
understanding the disease process. It is now clear, however, that
alterations in the normal function of PrPC may play a crucial
role in causing or contributing to the disease phenotype. For this
reason, elucidating the physiological activity of PrPC has
become a major priority in the prion field. In this review, we
have discussed each of the major functions that have been
proposed for PrPC. Although the evidence is not conclusive for
any them, we have emphasized the anti-apoptotic activity of
PrPC as being of particular interest, because it has been demon-strated in a variety of experimental systems, from yeast to mice.
In addition, there is evidence that loss or subversion of this
activity may be related to neuronal death in prion diseases.
Understanding the normal function of PrPC has important
implications for the therapy of prion disorders. At present, most
therapeutic strategies are directed at inhibiting the formation of
PrPSc [166]. If alterations in PrPC function play an important
role in prion-induced pathology, then an alternative approach is
to target the cellular pathways mediating the biological actions
of PrPC. In this regard, it might be possible to use the
physiological activity of PrPC to develop in vitro assays to
screen for drugs that have therapeutic potential. In addition, if
the toxicity of PrPSc is partly attributable to a loss of PrP
function, then over-expression of wild-type PrP may represent a
strategy for suppressing the disease phenotype. Conversely,
reduction of PrP expression, a strategy that has been proposed
for preventing or treating prion diseases [153,167], may have
detrimental consequences due to loss of the neuroprotective
activity of PrPC.
Future progress in understanding the normal function of
PrPC will require identification of physiologically relevant PrP-
interacting partners, and elucidation of the cellular pathways in
which they participate. Accomplishing these objectives is likely
to be facilitated by the use of model systems such as yeast [43]
and Drosophila [168] that are amenable to genetic analysis, as
well as by the development of additional cultured cell and
transgenic mouse models. Given the rapid pace of work in the
prion field, new discoveries will certainly be forthcoming.
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